QUANTUM GENOMICS: Quantum Genomics announces the presentation of the results of its phase III FRESH study, in difficult to treat/resistant hypertension, on November 4, 2022 at the annual meeting of the American Heart Association (AHA) – 09/19/2022 at 07:30


Quantum Genomics Announces Results Presentation

of its phase III FRESH study, in difficult-to-treat/resistant hypertension,

November 4, 2022 at the American Heart Association (AHA) Annual Meeting

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC)

a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain to treat difficult to treat/resistant hypertension and heart failure, announces the presentation of the results of its phase III FRESH study, in difficult to treat and resistant hypertension, in the “Late-breaking trials” session at the annual meeting of the American Heart Association (AHA) in Chicago (US).

The results of the phase III FRESH study will be presented on November 4, 2022 in the “Late-breaking trials” session by the principal investigator of the study, Pr BAKRIS, Professor of Medicine and Director of “AHA2 comprehensive hypertension center” at the University of Chicago (USA).

Bruno Besse, Medical Director of Quantum Genomics, says:

“The presentation of the results of the FRESH study at a conference as prestigious as that of the American Heart Association demonstrates once again the interest of the scientific community for a new therapeutic class, such as that represented by firibastat, in the management of difficult-to-treat and resistant arterial hypertension, a condition for which there is little or no therapeutic alternative. »

The results of the FRESH study, presented at the AHA congress, will constitute a first key step towards filing the registration dossier with the American and European authorities.

The FRESH study is indeed the first pivotal phase III study aimed at evaluating the efficacy and safety of firibastat in the treatment of difficult to treat and resistant arterial hypertension. 515 eligible patients with difficult-to-treat or resistant hypertension were randomized to 69 hospitals in Europe, Canada, the United States and Latin America.

Recruitment of the REFRESH study, the second pivotal phase III study of long-term efficacy and safety, with the once-daily formulation of firibastat, is progressing normally.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (about 30% of patients are poorly controlled or fail treatment), and heart failure (one out of two diagnosed patients dies within five years).

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).

More information on www.quantum-genomics.com, our Twitter and Linkedin accounts

contacts

Quantum Genomics

[email protected]

Communication building (EUROPE)

Financial communication and media

[email protected]

LifeSci (US)

Mike Tattory

Media communications

+1 (646) 751-4362 – [email protected]


This post has the “? Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

x2eclZyblpudynJslMhoZ2SWaZyTmmWZZmnGlpZtl5mZmW+TyW9pZseWZnBnl2lo

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Other press releases


Full and original press release in PDF format:

https://www.actusnews.com/news/76242-cp-acceptance-aha-3.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86